. pul



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: FROSTEGARD=1C

In re Application of:

Johan FROSTEGARD

Appln. No.: 10/814,194

Appln. No.: 10/814,194

Filed: April 1, 2004

For: METHOD OF DIAGNOSING SPONTANEOUS ABORTION

Atty. Docket: FROSTEGARD=1C

Confirmation No.: 6446

)

Examiner:

Washington, D.C.

December 2, 2005

INFORMATION DISCLOSURE STATEMENT [IDS]

Customer Service Window, Mail Stop Amendment Honorable Commissioner for Patents U.S. Patent and Trademark Office Randolph Building 401 Dulany Street Alexandria, Virginia 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits.
- 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not

In re Appln. No. 10/814,194

require to be filed unless specifically required by the Office, a copy of each document listed is attached.

- 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Sheridan Neimark

Registration No. 20,520

SN:jec

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

G:\BN\B\Bran\frostegardlC\pto\ids 02 Dec 05.doc



Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of | 1

Complete if Known		
Application Number	10/814,194	
Filing Date	April 1, 2004	
First Named Inventor	Johan FROSTEGARD	
Group Art Unit	1643	
Examiner Name		
Attorney Docket Number	FROSTEGARD =1C	_

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	AL	A. ALBERTINI, et al; "Cost/Benefit and Predictive Value of Radioimmunoassay"; Symposia of the Giovanni Lorenzini Foundation; Vol. 18, pages 23-27.		
Examir Signati	ner ure	Date Considered		

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.